Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma
- The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's (NASDAQ: ALLO) ALLO-715 to treat multiple myeloma.
- In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
- ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
- Price Action: ALLO shares are down 2.35% at $20.75 during the market session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs multiple myeloma Orphan Drug DesignationBiotech News Health Care FDA General
